Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications VST Cells

Publication Date: December 27, 2018

Leukoreduction system chambers are a reliable cellular source for the manufacturing of T-cell therapeutics

Leukoreduction system chambers (LRSCs) discarded after plateletpheresis supply peripheral blood mononuclear cells (PBMCs) that perform like paired blood samples for manufacturing virus-specific T cells. Each LRSC gave about 1.3 billion PBMCs, and T-cell subsets in five donors matched blood, except for transiently lower CD62L on fresh LRSC cells. After anti-CD3/CD28 stimulation, T cells expanded 6.6-fold from LRSCs and 5.9-fold from blood after 7 days in culture. Cultures of 15 × 10^6 PBMCs with CMV pp65 peptides grew 6.7-fold (LRSC) and 5.1-fold (blood) over 14 days, and fresh and cryopreserved cells performed comparably. LRSC-derived dendritic cells also primed CMV-specific T cells from…

Download Now →

Author: Gabrielle Boudreau, Cédric Carli +5 more

Publications CAR T Cells G-Rex®10

Publication Date: December 12, 2018

Overcoming Target Driven Fratricide for T Cell Therapy

NKG2D-CAR T cells (NKR-2) undergo target-driven fratricide during manufacture, and both a PI3K inhibitor and an anti-NKG2D blocking antibody limit it, with the antibody giving the better cell yield. In an initial experiment, expansion was 2.6-fold without blockade and 13.8-fold with the antibody. The inhibitor LY294002 lowered surface NKG2D to control levels at 10 μM and improved viability after cryopreservation, but yields stayed poor and it reduced proliferation of control T cells. Adding the antibody on day 6 instead of day 4 gave a CD4/CD8 ratio similar to the inhibitor process, with expansion comparable to control T cells and comparable cytokine secretion and cytolytic activity again…

Download Now →

Author: Eytan Breman, Benjamin Demoulin +16 more

Publications TIL Cells G-Rex®100M-CS, G-Rex®24 Well Plate

Publication Date: December 1, 2018

Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process

Moffitt Cancer Center describes process changes that shorten and partly close the manufacturing of tumor-infiltrating lymphocytes for melanoma. Adding agonistic anti-4-1BB antibody to pre-REP tumor-fragment cultures increased the share of fragments with TIL outgrowth and the viable TIL yield. Moving the 14-day rapid expansion from T175 flasks and bags to G-Rex® 100MCS flasks gave 2310-fold expansion versus 729-fold, with 85% versus 74% viability at day 14. A phase 1 trial combining both changes shortened culture from 51 to 37 days and let all patients reach the 60 × 10^9 cell dose, versus 40% with traditional methods. Replacing polystyrene 24-well plates with gas-permeable G-Rex® plates f…

Download Now →

Author: Emily L. Hopewell, Cheryl Cox +2 more

Publications B Cells, TIL Cells

Publication Date: November 20, 2018

CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors

Antibodies produced by tumor-infiltrating B cells from patients with pancreatic cancer or brain tumors recognize cytomegalovirus and Epstein-Barr virus peptides differently from serum antibodies. Peptide microarrays covering CMV pp65 and four EBV proteins were probed with serum from 15 patients and B-cell culture supernatants from 18 patients. Tumor-derived IgG recognized a much broader set of epitopes, with EBNA3 giving the most hits, whereas serum IgG was more restricted and recognition varied strongly between patients. Tumor-infiltrating lymphocytes from four patients were tested against the top five peptides; in one pancreatic cancer patient, the EBNA-3a peptide KRPPIFIRRLHR elicited…

Download Now →

Author: Qingda Meng, Davide Valentini +3 more

Publications CAR T Cells

Publication Date: November 5, 2018

Phase 1 Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

A single infusion of autologous NKG2D-CAR T cells, given without lymphodepleting chemotherapy, was feasible and safe in a phase 1 dose-escalation trial of 12 patients, 7 with AML and 5 with multiple myeloma. Four dose levels spanned 1 × 10^6 to 3 × 10^7 viable T cells. Manufacturing succeeded for all 12 patients who underwent T-cell collection, with median NKG2D-CAR expression of 75% on CD3+ cells. No dose-limiting toxicities, cytokine release syndrome or CAR T cell–related neurotoxicity occurred, and no grade 3 or higher event was attributed to the CAR T cells. No objective tumor responses were seen, and CAR T-cell expansion and persistence were limited. One AML patient at the highest do…

Download Now →

Author: Susanne H. Baumeister, Joana Murad +19 more

Publications TIL Cells G-Rex®10

Publication Date: November 1, 2018

Utilizing T-cell activation signals 1, 2 and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma

Adding agonistic anti-4-1BB (Urelumab) and anti-CD3 (OKT3) antibodies to high-dose IL-2 during the initial pre-REP phase of TIL expansion shortened culture and raised success rates in cutaneous and uveal melanoma. Tumor fragments from 16 cutaneous and 12 uveal melanoma patients were cultured in G-Rex® 10 flasks and compared with standard IL-2-only culture in 24-well plates. The three-signal method reached an average culture duration of 14.7 ± 2.6 days versus 30.9 ± 6.1 days for the clinical method, using only five fragments rather than about twenty. All 12 uveal melanoma cultures expanded successfully, in 15.8 ± 2.3 days. CD8+ TIL predominated (mean 84.9 ± 9.6%), and 4 of 5 cutaneous TIL…

Download Now →

Author: René J. Tavera, Marie-Andrée Forget +20 more

Publications CAR T Cells

Publication Date: July 12, 2018

TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy

Anti-CD3 chimeric antigen receptor (3CAR) T cells can be manufactured only if the TCRαβ/CD3 complex is disrupted by TALEN gene editing before lentiviral transduction. Reversing that order caused T-on-T killing and poor yields. With the correct sequence, 57% of T cells expressed 3CAR within 7 days, and cultures self-enriched for TCR-negative cells, with under 0.2% residual TCR-positive cells. Cells expanded 100-fold over 11 days in a gas-permeable flask. In vitro, 3CAR T cells killed CD3-positive Jurkat cells, healthy donor T cells and primary childhood T-ALL samples (6 of 6). In immunodeficient mice, they cleared CD3-positive Jurkat leukemia in 5 of 5 treated animals by day 18.

Download Now →

Author: Jane Rasaiyaah, Christos Georgiadis +3 more

Publications CAR T Cells G-Rex®100

Publication Date: June 29, 2018

Manufacturing development and clinical production of NKG2D Chimeric Antigen Receptor-expressing T cells for autologous adoptive cell therapy

A 9-day gamma-retroviral process produced autologous NKG2D CAR T cells that met release criteria in every healthy-donor and patient run, supporting a first-in-human Phase I trial in relapsed acute myeloid leukemia and multiple myeloma. OKT3-activated T cells were transduced twice and expanded with IL-2 in gas-permeable G-Rex® flasks. Across 12 enrolled patients, products had a median T-cell purity of 98%, median transduction of 66% in CD8+ and 93% in CD4+ cells, and a median 8-fold CD3+ expansion, with a median 13.8 × 10^7 CD3+ cells harvested at 80% viability. Products secreted IFN-γ against NKG2D ligand-positive tumor cell lines, and NKG2D-blocking antibodies reduced it. Cell viability,…

Download Now →

Author: Joana M. Murad, Susanne H. Baumeister +15 more

Publications TIL Cells G-Rex®100M

Publication Date: May 30, 2018

Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome

In 74 metastatic melanoma patients treated with autologous tumor-infiltrating lymphocytes (TIL) at a single center, prior anti-CTLA4 exposure was linked to poorer outcomes after cell therapy. Best overall response was 42% for the whole cohort, 47% in checkpoint-naïve patients and 38% after anti-CTLA4 alone. Median overall survival was 24.6 months in CTLA4-naïve versus 8.6 months in CTLA4-exposed patients, and the latter received fewer TIL. Higher infused TIL numbers, CD8 predominance and BTLA expression correlated with response only in anti-CTLA4-naïve patients. Baseline serum IL-9 above 5.3 pg/mL predicted response in 7 of 9 patients, whereas TIL persistence, tumor recognition and mutati…

Download Now →

Author: Marie-Andrée Forget, Cara Haymaker +45 more

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: May 10, 2018

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

Breast cancer-directed T cells were engineered with a CAR against MUC1 plus an inverted cytokine receptor that converts the immunosuppressive IL4 signal into an IL7-type growth signal. First-generation CAR cells with the receptor expanded in IL4 but became exhausted, with PD-1 and TIM3 upregulation, and did not control tumors. Cells carrying a second-generation 41BB.CD3ζ CAR together with the receptor expanded, kept CD25 expression and sustained killing after 21 days of co-culture. In mice bearing IL4-producing MDA MB 468 tumors, every animal given these cells became tumor-free, and cell numbers fell after clearance. Tumor rechallenge re-expanded the cells only at the IL4-producing site.

Download Now →

Author: Pradip Bajgain, Supannikar Tawinwung +8 more

Publications Treg Cells

Publication Date: May 9, 2018

A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants

Nine living donor kidney transplant recipients received ex vivo expanded autologous polyclonal regulatory T cells in a three-tier phase I dose-escalation trial (0.5, 1 and 5 × 10^9 cells, three recipients per tier), and no serious adverse events attributable to the infusion occurred. Tregs were isolated from cryopreserved leukapheresis products with the CliniMACS system and expanded for 21 days with Exp-Act beads, IL-2, TGF-β and sirolimus. All nine products met or exceeded the IND-approved release criteria and showed FOXP3 expression above 80%. Infusion on day 60 raised circulating Treg percentages 5 to 20 fold, sustained in most patients to one year. No clinical rejection events occurre…

Download Now →

Author: James M. Mathew, Jessica H.-Voss +9 more

Publications DC Cells

Publication Date: April 19, 2018

Bags versus: a comparison of cell culture systems for the production of dendritic cell–based immunotherapies

This review compares polystyrene flasks with closed fluoropolymer bags for producing monocyte-derived dendritic cell immunotherapies and concludes that vessel choice can affect product quality. Most studies comparing bag and flask cultures found no marked difference in the dendritic cells generated, although some reported differences in CD1a expression or in IL-10 and IL-12 production. Fluoropolymer bags are closed, flexible and gas-permeable, which lowers contamination risk, whereas polystyrene has an elastic modulus of about 3 GPa compared with roughly 500 MPa for fluorinated ethylene propylene. Sipuleucel-T, the first approved cell-based cancer vaccine, was made in fluoropolymer bags a…

Download Now →

Author: Natalie Fekete, Ariane V. Béland +3 more